TITLE

Osteoporosis medications and the risk of developing jaw complications

PUB. DATE
May 2007
SOURCE
Journal of the American Dental Association (JADA);May2007, Vol. 138 Issue 5, p692
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article examines the risks of jaw complications associated with the use of oral bisphosphonates for treating osteoporosis. According to the author, the true risk posed by oral bisphosphonates remains uncertain, but some researchers agree that the perceived risk is quite negligible. The most common complications associated with the medications are discussed.
ACCESSION #
25203323

 

Related Articles

  • Clodronic acid/pamidronic acid/zoledronic acid.  // Reactions Weekly;10/3/2009, Issue 1272, p13 

    The article examines 6 cases of osteonecrosis of the jaw (ONJ) caused by clodronic, pamidronic and zoledronic acids. Due to osteoporosis or bone metastases, 3 men and women aged 59-80 were administered with bisphosphonate therapy. Five cases escalated into (ONJ) due to IV zoledronic acid...

  • Osteonecrosis of the Jaw -- New Side-Effect to Bisphosphate Use. Elliott, William T. // Clinical Oncology Alert;Jan2007 Pharmacology Watch, p2 

    The article discusses findings of a study that appeared in the November 30, 2006 issue of the "New England Journal of Medicine," which examined a side effect of biphosphonate, a drug for preventing and treating osteoporosis. The side effect being studied is osteonecrosis of the jaw, which is...

  • Bisphosphonate-Related Osteonecrosis of the Jaws An Old Disease With a New Drug? Carlson, Eric R. // CRANIO: The Journal of Craniomandibular & Sleep Practice;Jan2010, Vol. 28 Issue 1, p1 

    The author focuses on the development of osteonecrosis of the jaws in patients receiving bisphosphonate therapy. Oral bisphosphonates are said to be approved to treat osteoporosis and prevent hip and spine fractures from 40-70%. Based on two studies conducted in the U.S., the incidence of...

  • Alendronic acid.  // Reactions Weekly;9/27/2008, Issue 1221, p7 

    The article describes the case of a 74-year-old woman who developed jaw osteonecrosis while being treated with alendronic acid for osteoporosis. The patient presented with pain and persistent abnormal exposure of her jaw bone several months after extraction of her left mandibular and molars. Her...

  • Risk Factors and Indices of Osteomyelitis of the Jaw in Osteoporosis Patients: Results from a Hospital-Based Cohort Study in Japan. Yamazaki, Toru; Yamori, Masashi; Tanaka, Shiro; Yamamoto, Keiichi; Sumi, Eriko; Nishimoto-Sano, Megumi; Asai, Keita; Takahashi, Katsu; Nakayama, Takeo; Bessho, Kazuhisa // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Background:Several studies have reported osteomyelitis of the jaw (OMJ) as a side effect of bisphosphonates (BPs), and the risk of oral BPs has been recently clarified. However, other systemic risk factors of OMJ remain unclear. Importantly, the possibility of risk classification based on the...

  • Managing the adverse effects of bisphosphonate therapy on the jaw. Rizzolo, Denise; Sedrak, Mona // JAAPA: Journal of the American Academy of Physician Assistants (;Nov2009, Vol. 22 Issue 11, p48 

    The article focuses on the effects of treating bone loss from osteoporosis and osteopenia therapy using bisphosphonates. It states that patients taking bisphosphonates developed a bisphosphonate-related osteonecrosis of the jaws (BRONJ). It notes that BRONJ patients must undergo a comprehensive...

  • Bisphosphonates.  // Reactions Weekly;10/3/2009, Issue 1272, p10 

    The article presents 31 case studies of osteonecrosis of the jaws caused by bisphosphonates. They are alendronic acid, pamidronic acid, clodronic acid and zoledronic acid. Three cases were reported to have multiple bone osteolythic lesions and the others developed single lesions. Continued...

  • Alendronic acid.  // Reactions Weekly;4/23/2005, Issue 1048, p6 

    Discusses a case report of a 43-year-old woman who developed secondary hyperparathyroidism during treatment with alendronic acid for osteoporosis. Reference to a study by H. Haerian et al, published in the January 2005 issue of the "Journal of Investigative Medicine"; Dosage of alendronic acid...

  • Zoledronic acid.  // Reactions Weekly;3/11/2006, Issue 1092, p26 

    Discusses research on severe uveitis that was developed by a 60-year-old woman after treatment with zoledronic acid for osteoporosis. Reference to a study published in the December 2005 issue of "Cancer"; Signs and symptoms manifested by the patient; Dosage of zoledronic acid being taken by the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics